1975
The American Burkitt Lymphoma Registry: a progress report.
Levine P, Connelly R, Berard C, O'Connor G, Dorfman R, EASTON J, DeVita V. The American Burkitt Lymphoma Registry: a progress report. Annals Of Internal Medicine 1975, 83: 31-6. PMID: 1147436, DOI: 10.7326/0003-4819-83-1-31.Peer-Reviewed Original ResearchConceptsLymphoma RegistryAfrican patientsAmerican patientsBurkitt's lymphomaEpstein-Barr virus titersPeripheral lymph node involvementAbrupt clinical presentationEpstein-Barr virus genomeHigh-dose cyclophosphamideLymph node involvementAmerican Burkitt's lymphomaCentral nervous systemPredominance of menPathologic reviewClinical presentationLymphocytic lymphomaAbsence of casesNonendemic regionsGastrointestinal tractNervous systemLymphomaPatientsVirus titersMore casesTime-space clustering
1974
Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide
Young R, Canellos G, Chabner B, Schein P, Hubbard S, DeVita V. Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide. Gynecologic Oncology 1974, 2: 489-497. PMID: 4376998, DOI: 10.1016/0090-8258(74)90059-6.Peer-Reviewed Original ResearchConceptsAdvanced ovarian carcinomaComplete remissionMedian durationOvarian carcinomaLong-term disease-free survivalTerm disease free survivalHigh-dose cyclophosphamideDisease-free survivalProspective Randomized ComparisonDose cyclophosphamideIntravenous cyclophosphamideIntensive regimenMelphalan therapyFree survivalInitial remissionMedian survivalUnacceptable toxicityUntreated patientsAgent therapyRandomized comparisonPresent studyHigh dosePhenylalanine mustardRemissionChemotherapy